Shimmer Launches Verisense Pulse+
Shimmer Research has launched Verisense Pulse+, a new sensor for the Verisense platform. Verisense Pulse+ provides photoplethysmogram, galvanic skin response (GSR), and an inertial measurement unit. The Verisense platform can now measure clinical trial participants’ heart rate, oxygen saturation and emotional responses in addition to their activity and sleep levels.
The PPG sensor monitors heart rate by using light absorption to measure changes in participant capillary blood volume. Whereas the GSR sensor measures changes in sweat gland activity, which can be used to assess the participant’s level of psychological and emotional arousal, stress, and other emotional responses.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
